

## Supplemental Materials for

### **Stag2 regulates hematopoietic differentiation and self-renewal through alterations in gene expression and topological control**


**Authors:** Aaron D. Viny<sup>1,2,3</sup>, Robert L. Bowman<sup>1,3</sup>, Yu Liu<sup>4</sup>, Vincent-Philippe Lavallée<sup>5</sup>, Shira E. Eisman<sup>1,3</sup>, Wenbin Xiao<sup>1,6</sup>, Benjamin H. Durham<sup>1,6</sup>, Anastasia Navitski<sup>1,3</sup>, Jane Park<sup>3</sup>, Stephanie Braunstein<sup>1,3</sup>, Besmira Alija<sup>1,3</sup>, Abdul Karzai<sup>1,3</sup>, Isabelle S. Csete<sup>1,3</sup>, Elham Azizi<sup>5</sup>, Matthew Witkin<sup>3</sup>, Timour Baslan<sup>7</sup>, Christopher J. Ott<sup>8</sup>, Dana Pe'er<sup>5</sup>, Job Dekker<sup>4,9</sup>, Richard Koche<sup>3</sup>, Ross L. Levine<sup>1,2,3\*</sup>

Correspondence to: [leviner@mskcc.org](mailto:leviner@mskcc.org)

#### **This PDF file includes:**

Figs. S1 to S7  
Captions for Data S1 to S7  
Table Legend for Table S1


# Supplemental Fig. 1





**Supplemental Fig 1. (Related to Figure 1).** Schematic representing the conditional knockout allele for **A)** Stag2 and **B)** Stag1 with each containing LoxP sites flanking exon 7. Digital PCR of blood genotyped for **C)** Stag2 or **D)** Stag1 from WT, floxed, and excised genotypes. **E)** RT-PCR measuring gene expression of Stag2 or **F)** Stag1 in floxed, heterozygous, and homozygous deletion. **G)** Full length western blot for Stag2 and **H)** Stag1 in floxed and excised bone marrow. **I)** Stag2 KO, but not Stag1 KO mice have increased hematopoietic stem cells as enumerated for each of the SLAM populations MPP, LT-HSC, and ST-HSC. **J)** Myeloid Progenitors (Lin<sup>-</sup>Kit<sup>+</sup>Sca1<sup>-</sup>) show expanded granulocyte-macrophage precursors (GMP) at the expense of megakaryocyte-erythroid precursors (MEP). **K)** Representative flow cytometry scatter-plots of Stag2 floxed, heterozygous, and KO bone marrow (Parent gate is Lin<sup>-</sup> live singlets) showing increased LSK. Myeloid progenitors are gated by Cd34 and Fc- $\gamma$  revealing increased granulocyte-macrophage precursors (GMP) and reduced megakaryocyte-erythroid progenitors (MEP). Competitive bone marrow transplantation of **L)** Stag2 WT or **M)** KO bone marrow mixed 1:1 with Cd45.1 normal marrow. Mice were injected with PIPC following engraftment at week 2. Flow cytometry of peripheral blood measured Cd45.2 chimerism every 4 weeks and **N)** at 16 weeks in the bone marrow. Competitive bone marrow transplantation of **O)** Stag1 WT or **P)** KO bone marrow mixed 1:1 with Cd45.1 normal marrow shows no difference in chimerism in peripheral blood **Q)** or in the bone marrow at 16 weeks.


## Supplemental Fig. 2




**Supplemental Fig 2. (Related to Figure 1)** **A)** Cytogenetic analysis of Stag2 and **B)** Stag1 KO mice. Representative metaphase spreads depicted for each genotype. All metaphase karyotypes were 40,XX [20] for Stag2 WT (n=4), Stag2 KO (n=3), Stag1 KO (n=3), and 40,XY [20] for Stag2 WT (n=3) and Stag2 KO (n=4). One of three Stag1 WT samples had a single tetraploid metaphase (40,XX[19], 80,XXXX [1]), and normal 40,XX [20] in the remaining two samples. **C)** Morphologic analysis of 100 metaphase figures for the presence of premature sister chromatid separation shows that more Stag2 KO cells had premature sister chromatid separation (mean=13.5%,  $p < 0.001$ ). **D)** Low depth whole genome sequencing of Stag2 WT and KO bone marrow for copy number shows no alterations genome wide in Stag2 WT females (n=4), Stag2 KO females (n=3), or **E)** Stag2 WT males (n=3). One of four Stag2 KO males shows a small 2Mb deletion at chr11qE2, and 3 have no alterations genome wide. **F-G)** RT-PCR measuring gene expression of (F) Stag1 or (G) Stag2 in floxed, heterozygous, and homozygous deletion of the opposing Stag gene. Stag1 expression increases in Stag2 KO bone marrow (student's t test,  $p < 0.03$ ), but Stag2 expression does not change with Stag1 deletion ( $p < 0.65$ ). Western blot for Stag2 and Stag1 in **H)** Stag2 and **I)** Stag1 floxed and excised bone marrow. **J)** Patients with acute myeloid leukemia from The Cancer Genome Atlas with STAG2 mutations have higher levels of STAG1 expression compared to patients without cohesin mutations ( $p < 0.006$ ). **K)** Peripheral blood counts of Stag2 WT and KO mice with heterozygous or homozygous co-deletion of Stag1 taken at 7 days following PIPC (at the time Stag2/Stag1 KO mice were moribund) reveal decreased leukocytes in Stag2/Stag1 KO ( $p < 0.001$ ) and platelets in both Stag2 KO/Stag1<sup>-/+</sup> ( $p < 0.001$ ) and Stag2/Stag1 KO ( $p < 0.001$ ). **L)** Representative metaphase spreads depicted for male Stag2/Stag1 KO with chromosomal catastrophe.

# Supplemental Fig. 3

A




B



C




D Cluster Assignment



F

Gene Ontology	Name	NES	FDR q-value
GO: 0032728	NUCLEOSOME ORGANIZATION	3.897425	0
GO: 0063233	DNA PACKAGING	3.882068	0
GO: 0063204	PROTEIN-DNA COMPLEX ASSEMBLY	3.864702	0
GO: 0063234	NUCLEOSOME ASSEMBLY	3.806585	0
GO: 0031497	CHROMATIN ASSEMBLY	2.855205	0
GO: 0063333	CHROMATIN ASSEMBLY OR DISASSEMBLY	2.849115	0
GO: 0007059	CHROMOSOME SEGREGATION	2.321101	0


Cell cycle




G

Gene Ontology	Name	NES	FDR q-value
GO: 0042113	B CELL ACTIVATION	2.303323	0
GO: 0030908	LYMPHOCTE DIFFERENTIATION	2.319757	0
GO: 0042110	T CELL ACTIVATION	2.3201916	0
GO: 0030217	T CELL DIFFERENTIATION	2.235279	0
GO: 0002521	LEUKOCYTE DIFFERENTIATION	2.233351	0
GO: 0044087	REGULATION OF CELLULAR COMPONENT BIOGENESIS	2.038425	0
GO: 0042113	B CELL ACTIVATION	2.303323	0



Lymphoid




H



I










E



**Supplemental Fig 3. (Related to Figure 1)** **A)** Volcano plot for differentially expressed genes by RNA sequencing in LSK cells of Stag2 WT and Stag2 KO. Genes decreased in expression in Stag2 KO in blue (n=186) and genes increased in expression in Stag2 KO in red (n=42). **B)** Gene-set enrichment analysis of LSK RNAseq shows decreased expression of the GO Cell Fate Specification gene set. **C)** t-SNE projection of library-size normalized and log transformed data for complete collection (24,153 cells). Each dot represents a single cell colored by Phenograph clustering (Levine et al., 2015). **D)** Pearson correlation between centroids of Phenograph clusters to standardized bulk RNA-sequencing data from selected sorted mouse hematopoietic cells populations (from Haemopedia-Mouse RNAseq (de Graaf et al., 2016)). **E)** Heatmap of normalized and log transformed expression of top 20 differentially expressed genes per inferred lineage; cells and genes are hierarchically clustered. Differential expression was determined by calculating, for every gene, the Wasserstein distance between normalized and log-transformed expression in cells from inferred lineage and all other cells; top heatmaps show assignment of cells to clusters and inferred lineages labeled in Figure 2D. **F)** Gene set enrichment meeting threshold of NES >2, FDR <0.25 for positive enrichment (top) and **G)** negative enrichment (bottom) with gene ontology. T-SNE for top 10 genes influencing the positive and negative principle component are shown. **H)** Single cell RNA seq data from Cabezas- Wallscheid et al. Genes increased in Stag2 KO LSK are enriched for genes expressed in active HSC and downregulation of quiescent genes. **I)** Comparisons to single cell RNAseq further refines the decreased expression in stage 1 of the dHSC (X1) compared to stages 2-4 (vs X2 p=2.8 x 10<sup>5</sup>; vs X3 p=1.9 x 10<sup>5</sup>; vs X4 p=2.5 x10<sup>6</sup>). Statistical comparisons were generated using pairwise Student's t-test.

# Supplemental Fig. 4




**H**

TF	Motif	% Target/ % Background	P-value
PU.1		62.5% / 26.6%	1e-15
CEBPB		28.3% / 5.97%	1e-13

**Supplemental Fig 4. (Related to Figure 2)** **A)** Peripheral blood counts of Stag2 and Stag1 WT and KO mice taken at 8 weeks following PIPC treatment reveal decreased leukocytes ( $p < 0.02$ ) and platelets ( $p < 0.01$ ) in Stag2 KO mice and no changes in Stag1 KO mice. No differences in hemoglobin were seen in either Stag2 or Stag1 KO. **B)** Flow cytometric analysis of erythroid development using Ter-119 and Cd71 showing reduced mature erythroid populations (EryA  $p = 0.002$ ; EryB  $p = 0.007$ ; EryC  $p = 0.005$ ) in Stag2 KO bone marrow. **C)** Representative flow cytometry scatter-plots of Stag2 WT / KO and Stag1 WT / KO bone marrow showing Stag2 KO cells fail to decrease in FSC during maturation (Parent Gate on Ter-119<sup>+</sup> Cells). **D)** Heatmap of bulk RNA-sequencing data for cells with progressive erythroid lineage commitment (from GSE60101 (Lara-Astiaso et al., 2014)) showing normalized and standardized expression of genes most correlated or anticorrelated with erythroid maturation component. Correlations were computed using the Pearson method. **E)** t-SNE projection of library-size normalized and log transformed data for inferred MEP subset (1787 cells). Each dot represents a single cell colored by expression of labelled genes. **F)** Heatmap of bulk RNA-sequencing data for cells with progressive granulocyte lineage commitment (from GSE60101 (Lara-Astiaso et al., 2014)) showing normalized and standardized expression of genes most correlated or anticorrelated with granulocyte maturation component. Correlations were computed using the Pearson method. **G)** t-SNE projection of library-size normalized and log transformed data for inferred granulocyte subset (6316 cells). Each dot represents a single cell colored by expression of labelled genes. **H)** HOMER analysis of common loci of decreased accessibility by ATACseq for Smc3 heterozygous loss and Stag2 KO show enrichment for PU.1 and CEBPB motifs.




# Supplemental Fig. 5





**Supplemental Fig 5. (Related to Figure 3)** Chromatin immunoprecipitation and sequencing for **A)** Ctf **B)** Smc1a and **C)** Smc3 in Stag2 WT (n=2) and KO (n=2) HSPC. Volcano plots show lack of statistically significant differential loci. Heatmaps for **D)** Ctf and **E)** Smc1a (top row)/Smc3 (bottom row) at Stag2/Stag1 commonly bound sites. Heatmaps for **F)** Ctf and **G)** Smc1a (top row)/Smc3 (bottom row) at Stag2-uniquely bound sites. No differential occupancy in either Stag1/2 common or Stag2-unique sites were identified.

## Supplemental Fig. 6



**Supplemental Fig 6. (Related to Figure 5)** **A)** Insulation score changes (ISC: Insulation score KO – Insulation score WT) from Hi-C analysis of Stag2 WT and KO Lin<sup>-</sup> bone marrow using windows of 10kB. Stacked bar plot of genomic feature for common and Stag2-specific sites according to gain or loss of insulation. **B)** IGV track of the *Pax5* locus with Stag2 and Ctf binding at an intergenic locus that is lost in Stag2 KO and not bound by Stag1 either in WT or KO. **C)** ISC plotted across *Pax5* for Stag2 WT (n=2; shades of red) and KO (n=2; shades of blue) shows marked loss of insulation. **D)** Contact map of *Pax5* shows Stag2 KO cells lose local cis-interaction at two loci (arrows). **E)** Hi-C read counts for biologic replicates across WT and KO samples. The total valid interaction pairs for each sample are enumerated. No significant difference of sequencing depth was observed between samples. **F)** Enumeration of mature B cells (CD34-CD19+) and CD34+ blasts in STAG2 mutated MDS patients (n=11) compared to controls (n=15). **G)** Methylcellulose colony assay using IL-3, SCF, and IL-6 enriched media for stem cell replating. Stag2 WT and KO marrow were infected with lentivirus containing GFP-tagged empty vector, GFP-mycPU.1, or GFP-shPU.1. B-cell colonies were markedly larger and of higher cell output in Stag2 WT mycPU.1 transfected cells than in any other group. **H)** RT-PCR for *PU.1* and *Ebf1* after infection with GFP-tagged empty vector or GFP-mycPU.1 virus. Both Stag2 WT (p<0.01) and Stag2 KO (P<0.08) have increased *PU.1* expression in sorted GFP<sup>+</sup> cells. *Ebf1* increases in Stag2 WT cells infected with mycPU.1-GFP but *Ebf1* remains not detectable (N.D.) in Stag2 KO cells infected with either EV or mycPU.1 across 7 technical replicates. **I)** 20,000 GFP<sup>+</sup> cells from each condition were serially replated in M3434 Stemcell Methylcellulose. Overexpression and shRNA manipulation of PU.1 were unable to abrogate serial replating of the Stag2 KO cells. **J)** RT-PCR for *Ebf1* after infection with GFP-empty vector or Ebf1-GFP shows both Stag2 WT (p<0.02) and Stag2 KO (Not detectable in GFP-EV) have increased *Ebf1* expression in sorted GFP<sup>+</sup> cells. PU.1 expression did not change. Asterisks indicate statistical significance (student's t test, \* p<0.05, \*\*p<0.01, \*\*\*p<0.001)

Table S1 (Related to Figure 5): Patient Characteristics

STAG2 mutant	Age	Gender	diagnosis	karyotype	Mutation
1	74	M	therapy related MDS/MPN, 7% blasts	Normal	STAG2/TET2/GATA2/SRSF2/ZRSR2
2	66	M	therapy related MDS, 6% blasts	normal	STAG2/DNMT3A/RUNX1/BCOR/BCORL1/U2AF1
3	67	M	MDS-EB1, 5% blasts	normal	STAG2/TET2/ASXL1/RUNX1/NRAS/SRSF2
4	68	M	CMML-1, 4% blasts	normal	STAG2/ASXL1/SF3B1/TET2/TP53/SRSF2
5	71	M	MDS-EB1, 6% blasts	normal	STAG2/TET2/RUNX1/NRAS/EZH2/PTPN11/ZRSR2
6	17	F	MDS-MLD, 2% blasts	normal	STAG2/BCOR/GATA2
7	58	F	therapy related MDS, 1% blasts	normal	STAG2/ASXL1/NRAS
8	53	F	MDS-EB1, 5% blasts	normal	STAG2/NPM1/CBL
9	77	M	MDS-MLD, 2% blasts	normal	STAG2/DNMT3A/ETV6/U2AF1
10	79	M	therapy related MDS-EB1, 9% blasts	47,XY,+8[20]	STAG2/TET2/RUNX1/NRAS/EZH2/ZRSR2
11	54	M	MDS-EB1, 8% blasts	normal	STAG2/ASXL1/IDH2/NRAS/SRSF2

Control	Age	Gender	diagnosis	karyotype	Mutation
1	82	F	anemia	normal	negative
2	78	F	anemia	normal	negative
3	81	M	anemia and thrombocytopenia	normal	negative
4	83	F	aplastic anemia	normal	negative
5	72	M	anemia	normal	negative
6	84	M	anemia	normal	negative
7	53	F	thrombocytopenia	normal	negative
8	52	M	anemia and leukopenia	normal	negative
9	64	M	thrombocytopenia	normal	negative
10	49	M	pancytopenia	normal	negative
11	54	F	pancytopenia	normal	negative
12	65	M	anemia and thrombocytopenia	normal	negative
13	72	F	anemia and thrombocytopenia	normal	negative
14	67	M	anemia and leukopenia	normal	negative
15	65	F	pancytopenia	normal	negative